Acquisitions -Narrative (Details) $ / shares in Units, $ in Millions		3 Months Ended		12 Months Ended
	Sep. 26, 2023 USD ($) ft² $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 27, 2023 USD ($)
Business Acquisition [Line Items]
Selling, general and administrative				$ 2,549.7	$ 2,403.6	$ 2,674.3
Long-term debt, gross		$ 7,217.3	$ 7,217.3	7,217.3
Goodwill		6,219.2	6,219.2	6,219.2	$ 5,749.0	$ 5,761.1
Reata Pharmaceuticals, Inc
Business Acquisition [Line Items]
Price per share | $ / shares	$ 172.50
Total transaction value	$ 6,602.9
Outstanding equity awards				983.9
Consideration transferred, equity compensation pre-acquisition services	590.5
Operating expenses	393.4
Selling, general and administrative	196.4
Research and development expense asset acquired	197.0
Inventory	$ 1,692.0	1,259.0	1,259.0	1,259.0			$ 1,300.0
Inventory amortization period	3 years
Measurement Period Adjustments, Inventory		(433.0)	31.5
Fair value indefinite lived intangible assets discount rate	14.30%
Operating lease area | ft²	327,400
Operating lease, contract term	16 years
Operating lease liabilities	$ 151.8	151.8	151.8	151.8			151.8
Remaining lease term	15 years
Operating lease assets	$ 122.4	121.2	121.2	121.2			121.2
Goodwill	1,057.3	464.5	464.5	464.5			464.5
Reata Pharmaceuticals, Inc | Secured Debt | The Credit Facility | Line of Credit
Business Acquisition [Line Items]
Long-term debt, gross	1,000.0
Reata Pharmaceuticals, Inc | Selling, general and administrative
Business Acquisition [Line Items]
Separately recognized transactions, additional disclosures, acquisition cost expensed				28.4
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)
Business Acquisition [Line Items]
Intangible assets:	3,600.0	4,200.0	4,200.0	4,200.0			4,200.0
Reata Pharmaceuticals, Inc | In-process research and development
Business Acquisition [Line Items]
Intangible assets:	1,900.0	2,300.0	2,300.0	2,300.0			2,300.0
Reata Pharmaceuticals, Inc | Priority review voucher
Business Acquisition [Line Items]
Intangible assets:	100.0	100.0	100.0	100.0
Reata Pharmaceuticals, Inc | Other clinical programs
Business Acquisition [Line Items]
Intangible assets:	$ 20.0	$ 40.0	$ 40.0	$ 40.0			$ 40.0